

Study on Outcome of Nucleotide Polymerase Inhibitor (Sofosbuvir) in Treatment of Chronic Hepatitis C Among Egyptian Cirrhotic and Non-cirrhotic Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree
In Internal Medicine*

By

Mariam Wagih Nagib Gerges

(M.B.B.CH)

Faculty of Medicine- Ain Shams University

Supervised By:

Prof. Dr. Mohammed Abd-Elmabood Mohammed

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine- Ain Shams University

Assistant Prof. Dr. Wesam Ahmed Ibrahim

Assistant Professor of Internal Medicine and Gastroenterology

Faculty of Medicine- Ain Shams University

Assistant Prof. Dr. Ahmed Elsaady khayyal

Assistant professor of Internal Medicine and Gastroenterology

Faculty of Medicine- Ain Shams University

**Faculty of Medicine
Ain Shams University**

2016



Acknowledgement

First, thank God for blessing this work until it has reached its end, as a part of his generous help throughout my life.

*I would like to express my sincere gratitude for **Prof. Dr. Mohammed Abd-Elmabood Mohammed**, professor of Internal Medicine, Gastroenterology and Hepatology, Faculty of Medicine Ain Shams University, for his great support, continuous encouragement and tremendous effect he has done in the meticulous revision of the whole work.*

*Words stand short to express my deep appreciation for **Prof. Dr. Wessam Ahmed Ibrahim**, Assistant professor of Internal Medicine, Gastro-enterology and Hepatology, Faculty of Medicine Ain Shams University who kindly helped & supported me in this study.*

*I would like also to extend my thanks to **Prof. Dr. Ahmed Elsaady Khayyal**, Assistant Professor of Internal Medicine, Gastroenterology and Hepatology, Faculty of Medicine Ain Shams University for his sincere guidance, remarkable & his great help.*

*I would like to thank **Prof. Dr. Ahmed El Sawy**, consultant of Gastroenterology and Hepatology of the Egyptian Armed Force for his great help & support.*

*My gratitude cannot be fulfilled without expressing to my deepest gratitude to my **father, mother, brothers, sisters and friends** who have been a constant source of love, concern, support and strength.*

Mariam Wagih Nagib

List of Contents

<i>Title</i>	<i>Page No.</i>
List of abbreviations	i
List of figures	iii
List of tables	vi
Introduction	1
Aim of work	4
Review of literature:	
Chapter 1	5
Chapter 2	50
Patients and methods	84
Results	95
Discussion	112
Summary	128
Conclusion	132
References	133
Arabic summary	—

List of Abbreviations

- ALT** Alanine amino transferase.
- ANA** Anti-Nuclear Antibody.
- ASMA** Anti-Smooth Muscle Antibody.
- AST** Aspartate amino transferase.
- CHC** Chronic Hepatitis C.
- CHB** Chronic Hepatitis B.
- CLD** Chronic Liver Disease.
- ECM** Extra-Cellular Matrix.
- EIA** Enzyme Immuno-assays.
- FDA** Food and Drug Adminestration.
- EASL** European Association for the Study of the Liver.
- AASLD**.... American Association for the Study of the Liver
Disease.
- WHO** World Health Organisation.
- RIBA** Recombinant Immunoblot Assays.
- HBV** Hepatitis B Virus.
- HAV** Hepatitis A Virus.
- HCC** Hepatocellular Carcinoma.
- HCV** Hepatitis C Virus.
- HEV** Hepatitis E Virus.

HVR..... Hyper Variable Regions.

HIV..... Human Immunodeficiency Virus.

IL28B Interleukin 28B.

INR..... International Normalized Ratio.

KPa..... KiloPascal.

LF Liver Fibrosis.

LS Liver Stiffness.

CTP..... Child-Turcotte-Pugh.

NASH..... Non Alcoholic Steatohepatitis.

HVPG..... Hepatic Vein Pressure Gradient.

EDHS..... Egypt Demographic and Health Study.

LSPS..... Liver stiffness Spleen diameter to Platelet ratio Score.

LLOQ..... Lower Limit Of Quantitation.

NNIs..... Non Nucleoside Polymerase Inhibitors.

NI..... Nucleoside Polymerase Inhibitors.

NPV Negative Predictive Value.

PCR..... Polymerized Chain Reaction.

DAA..... Direct Antiviral Agents.

PEG-INF. Pegylated Interferon

PT Prothrombin Time.

PTT Partial Thromboplastin Time.

AFP..... Alpha Fetoprotein.

PLT..... Platelets.

TGTriglycerides.

RBV.....Ribavirin.

RNARibonucleic Acid.

IFN..... Interferon.

SOFSofosbuvir.

LDV..... Ledipasvir.

BOC..... Boceprevir.

TLV.....Telaprevir.

SVR12.....Sustained Virological Response at week 12 after treatment.

SVR24.....Sustained Virological Response at week 24 after treatment.

HCV GT..... Hepatitis C Virus Genotype.

SVR.....Sustained Virological Response.

EVR.....Early Virological Response.

RVRRapid Virological Response.

SWEShear Wave Elasticity.

TE.....Transient Elastography.

US..... Ultrasonography.

CT..... Computed Tomography.

MRI..... Magnetic Resonance Imaging.

MRE Magnetic Resonance Elastography.

IQR..... Interquartile Range.

LRE..... Liver Related Events.

eGFR..... Estimated Glomerular Filtration Rate.

OBV/PTV/r+DSV... ombitasvir /paritaprevir/ribavirin and dasabuvir

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Prevalence of HCV infection	6
Figure (2):	HCV in Egypt compared to other countries in the world	9
Figure (3):	Structure of Hepatitis C Virus	13
Figure (4):	The hepatitis C viral genome	13
Figure (5):	Global distribution of HCV Genotypes	15
Figure (6):	Natural History of HCV	28
Figure (7):	Algorithm of HCV Diagnosis	29
Figure (8):	HCV testing algorithm	32
Figure (9):	(A) Normal liver, (B) Injured liver with fibrosis (Batalter and Brenner, 2005)	34
Figure (10):	Fibroscan device	37
Figure (11):	Technique and probe position	39
Figure (12):	Development of chronic hepatitis C therapy	56
Figure (13):	HCV life cycle & targets for directly acting antiviral agents (DAA)	58

Figure (14): The direct antiviral agents classes and the difference between them	58
Figure (15): Pelvi-abdominal ultrasound device and probe	88
Figure (26): Fibroscan device	89
Figure (17): Technique and probe position of Fibroscan	90
Figure (18): Flexible upper endoscopy	91
Figure (19): Degree of change of hemoglobin level among studied groups before and after antiviral treatment	101
Figure (20): Degree of change of WBCs count among studied groups before and after antiviral treatment	101
Figure (21): Degree of change of AST level among studied groups before and after antiviral treatment	102
Figure (22): Degree of change of ALT level among studied groups before and after antiviral treatment	102
Figure (23): Degree of change of serum cholesterol level among studied groups before and after antiviral treatment	103
Figure (24): Degree of change of AFP level among studied groups before and after antiviral treatment	103

Figure (25):	Degree of change of liver fibrosis by fibroscan in group I before and after antiviral treatment ...	105
Figure (26):	Degree of change of liver fibrosis by fibroscan in group II before and after antiviral treatment ..	105
Figure (27):	Average degree of change (%) of AST level among studied groups after antiviral treatment .	107
Figure (28):	Average degree of change (%) of serum albumin level among studied groups after antiviral treatment	107
Figure (29):	Adverse effects reported during antiviral treatment among studied groups	109

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Indications for treatment of chronic hepatitis C in 2015	53
Table (2):	Different Sofosbuvir studies	64
Table (3):	Approved HCV drugs in the European Union in 2015	71
Table (4):	Common adverse events during therapy with peg-inteferon 2-b or -2a plus ribavirin	77
Table (5):	Child-Turcotte-Pugh (CTP) Calculator	86
Table (6):	Quantitative PCR for HCV RNA	93
Table (7):	Comparison between studied groups as regard Age	96
Table (8):	Comparison between studied groups as regard Gender	96
Table (9):	Comparison between studied groups as regard Fibroscan before starting antiviral treatment	97
Table (10):	Comparison between studied groups as regard baseline laboratory data	98

Table (11): Comparison between different laboratory data before and after antiviral treatment among group I	99
Table (12): Comparison between different laboratory data before and after antiviral treatment among group II	100
Table (13): Degree of change of liver fibrosis by Fibroscan before and after antiviral treatment among the studied groups	104
Table (14): Comparison between studied groups as regard percent of change of different parameters	106
Table (15): Spectrum of adverse effects with antiviral treatment among studied groups	109
Table (16): Comparison between studied groups as regard SVR rate	110
Table (17): Relation between SVR12 and degree of fibrosis in group I	111
Table (18): Relation between SVR12 and degree of fibrosis in group II	111

INTRODUCTION

HCV infection is a serious health issue. Egypt has a very high prevalence of HCV and a high morbidity and mortality from chronic liver disease and cirrhosis. Approximately 20% of Egyptian blood donors are anti-HCV positive. Egypt has higher rates of HCV than neighboring countries as well as other countries in the world with comparable socioeconomic conditions and hygienic standards for invasive medical, dental, or paramedical procedures (**Lavanchy and McMahon, 2000**). The strong homogeneity of HCV subtypes found in Egypt (mostly 4a) suggests an epidemic spread of HCV. Since a history of injection treatment has been implicated as a risk factor for HCV, a prime candidate to explain the high prevalence of HCV in Egypt is the past practice of parenteral therapy for schistosomiasis (**Lavanchy and McMahon, 2000**).

Liver cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, which leads to portal hypertension and end-stage liver disease (**Schuppan and Afhdal, 2008**).

With great advancements in the therapeutic modalities used for the treatment of chronic liver diseases, the accurate assessment of liver fibrosis is a vital need for successful individualized management of disease activity in patients. Transient ultrasound Elastography (Fibroscan) is an ultrasound-based technology for quantitatively assessing hepatic stiffness that has been introduced

in the last several years (**Ziol et al., 2005**). Stiffness was significantly correlated with fibrosis stage (**Foucher et al., 2006**). Fibroscan is considered to be a reliable method for the diagnosis of significant fibrosis, severe fibrosis and cirrhosis (**Friedrich-Rust et al., 2008**).

Recent advances in the understanding of the natural history and pathophysiology of cirrhosis, and in treatment of its complications, have resulted in improved management, quality of life, and life expectancy of patients (**Schuppan and Afhdal, 2008**). The standard care for patients with HCV infection continues to include 24 to 48 weeks of treatment with peginterferon-alfa 2a and ribavirin. Treatment with interferon is associated with troublesome side effects, including influenza-like symptoms, depression, fatigue and cytopenias. A substantial proportion of patients with HCV infection are unable or unwilling to receive interferon-based regimen (**Gane et al., 2013**).

The addition of the recently approved directly acting antiviral agents telaprevir or boceprevir to pegylated interferon-alfa and ribavirin has resulted in improved sustained virologic response (SVR) rates; however, adverse reactions, high pill burdens, and drug interactions continue to make treatment challenging (**Bacon et al., 2011**). Furthermore, certain host and viral factors including black race, advanced liver fibrosis, *IL28B* CT or TT genotypes, high baseline HCV viral loads, and prior treatment experience appear to remain associated with poorer

treatment outcomes (**Poordad et al., 2013; Jacobson et al., 2011**).

Recent studies show that interferon-free, directly acting antiviral agent-only regimens can successfully achieve sustained virological response “SVR” (**Poordad et al., 2013**).

Sofosbuvir is an oral nucleotide analogue inhibitor of the HCV-specific NS5B polymerase with in vitro activity against all HCV genotypes (**Jacobson et al., 2013**). The viral kinetics during treatment were nearly identical in all treatment groups. Viral suppression was rapid in all patients, regardless genotype, status with respect of previous treatment, baseline viral load, race or ethnic group, IL28B status and presence or absence of interferon during the regimen (**Gane et al., 2013**).

The most common recorded adverse effects with Sofosbuvir plus Ribavirin regimen were headache, fatigue, insomnia, nausea, rash and anemia. Hematologic abnormalities were more common among patients who received interferon than among those who did not receive (**Gane et al., 2013**).

The pangenotypic antiviral efficacy of sofosbuvir supports the continued investigation of sofosbuvir with ribavirin in patients with HCV infection (**Gane et al., 2013**).